DK1549677T3 - FVII- eller FVIIa-varianter med forøget koagulationsaktivitet - Google Patents

FVII- eller FVIIa-varianter med forøget koagulationsaktivitet

Info

Publication number
DK1549677T3
DK1549677T3 DK03747838.5T DK03747838T DK1549677T3 DK 1549677 T3 DK1549677 T3 DK 1549677T3 DK 03747838 T DK03747838 T DK 03747838T DK 1549677 T3 DK1549677 T3 DK 1549677T3
Authority
DK
Denmark
Prior art keywords
fvii
variants
coagulation activity
fviia variants
increased coagulation
Prior art date
Application number
DK03747838.5T
Other languages
Danish (da)
English (en)
Inventor
Jesper Mortensen Haaning
Kim Vilbour Andersen
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of DK1549677T3 publication Critical patent/DK1549677T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK03747838.5T 2002-09-30 2003-09-26 FVII- eller FVIIa-varianter med forøget koagulationsaktivitet DK1549677T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41483602P 2002-09-30 2002-09-30
US47964203P 2003-06-19 2003-06-19
PCT/DK2003/000632 WO2004029091A2 (en) 2002-09-30 2003-09-26 FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY

Publications (1)

Publication Number Publication Date
DK1549677T3 true DK1549677T3 (da) 2011-07-18

Family

ID=32045297

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03747838.5T DK1549677T3 (da) 2002-09-30 2003-09-26 FVII- eller FVIIa-varianter med forøget koagulationsaktivitet

Country Status (9)

Country Link
US (1) US20060166874A1 (https=)
EP (1) EP1549677B1 (https=)
JP (1) JP4472526B2 (https=)
AT (1) ATE505487T1 (https=)
AU (2) AU2003266931B2 (https=)
CA (2) CA2840692A1 (https=)
DE (1) DE60336741D1 (https=)
DK (1) DK1549677T3 (https=)
WO (1) WO2004029091A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
WO2003093465A1 (en) 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
CA2519873C (en) 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
RU2373282C2 (ru) 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
JP4874806B2 (ja) 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006018204A1 (en) 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
EP1797192A1 (en) * 2004-09-29 2007-06-20 Novo Nordisk Health Care AG Modified proteins
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP2360171A1 (en) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
WO2007006808A1 (en) 2005-07-13 2007-01-18 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP5894722B2 (ja) 2005-09-01 2016-03-30 ノボ ノルディスク ヘルス ケア アーゲー 第ｖｉｉ因子ポリペプチドの疎水性相互作用クロマトグラフィ精製
JP5690047B2 (ja) * 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
JP2010513462A (ja) * 2006-12-20 2010-04-30 バイエル・ヘルスケア・エルエルシー 第ＶＩＩおよび第ＶＩＩａ因子組成物
EP1972687A1 (en) * 2007-03-23 2008-09-24 GenOdyssee Polynucleotides and polypeptides of human factor VII gene, SNPs
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
CA2683443A1 (en) 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
EP4061942A4 (en) * 2019-11-22 2023-12-20 Sigilon Therapeutics, Inc. MONOCLONAL CELL LINES EXPRESSING AN EXOGENEOUS SUBSTANCE AND THEIR USES

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
ATE180834T1 (de) * 1990-01-29 1999-06-15 Zymogenetics Inc Antikoagulierende proteine
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
JPH0720127A (ja) * 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
EP0699075B1 (en) * 1993-05-21 2001-12-12 Zymogenetics, Inc. MODIFIED FACTOR VII for inhibiting vascular restenosis and platelet deposition
CA2271232C (en) * 1996-11-08 2005-02-22 Oklahoma Medical Research Foundation Modified protein c and methods of use thereof
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
CA2739933A1 (en) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
MXPA03001984A (es) * 2000-09-13 2003-08-29 Novo Nordisk Healthcare Ag Variantes de factor vii de coagulacion humano.
BR0114373A (pt) * 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
WO2002038162A1 (en) * 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
WO2003093465A1 (en) * 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS

Also Published As

Publication number Publication date
WO2004029091A2 (en) 2004-04-08
DE60336741D1 (de) 2011-05-26
CA2502162A1 (en) 2004-04-08
CA2502162C (en) 2014-04-15
CA2840692A1 (en) 2004-04-08
ATE505487T1 (de) 2011-04-15
AU2003266931A1 (en) 2004-04-19
AU2010201266A1 (en) 2010-04-22
EP1549677B1 (en) 2011-04-13
JP4472526B2 (ja) 2010-06-02
JP2006517089A (ja) 2006-07-20
WO2004029091A3 (en) 2004-05-21
US20060166874A1 (en) 2006-07-27
AU2003266931B2 (en) 2010-01-21
EP1549677A2 (en) 2005-07-06

Similar Documents

Publication Publication Date Title
DK1549677T3 (da) FVII- eller FVIIa-varianter med forøget koagulationsaktivitet
ATE431403T1 (de) Fvii oder fviia varianten
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
DK1066036T3 (da) Midler med serotoninrelateret aktivitet til behandling af sövnapnö
DE602005021471D1 (de) Aufnahme von körperhaltungsinformationen zur therapiebeurteilung
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
DK1902141T3 (da) ADAMTS 13-holdige sammensætninger med thrombolytisk virkning
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
CY1111626T1 (el) ΠΑΡΑΛΛΑΓΕΣ ΠΟΛΥΠΕΠΤΙΔΙΩΝ ΠΑΡΑΓΟΝΤΑ VII ´H VIIa
WO2003100574A3 (en) Dental appliances and systems and methods for distributing dental appliances
HRP20100264T1 (hr) Varijante gla domene faktora vii ili viia
BR0315846A (pt) Tratamento farmacológico para apnéia do sono
ATE435657T1 (de) Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
SE0102147D0 (sv) New methods
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE394414T1 (de) Hemmstoffe des gerinnungsfaktors xa, ihre herstellung und verwendung
ATE279437T1 (de) Peptidantagonisten des faktors viia
ATE491442T1 (de) 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
ATE534399T1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl